Boehringer Ingelheim: HIV Infections trials
The registry lists 67 HIV Infections studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 24 have results posted.
Phase 1 14Phase 2 15Phase 3 13Phase 4 7No phase 21(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical PracticeCompletedNCT01524900Results posted
- Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersCompletedNCT01374802Phase 1Results posted
- Drug Drug Interaction of BI 201335 and TenofovirCompletedNCT01340196Phase 1Results posted
- Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific DataCompletedNCT01134939Results posted
- Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With ViramuneCompletedNCT00979420Results posted
- A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.CompletedNCT00976950Results posted
- A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.CompletedNCT00905489Phase 1Results posted
- Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected PatientsCompletedNCT00876733Results posted
- Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected PatientsCompletedNCT00819052Phase 3Results posted
- PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.CompletedNCT00736502Results posted
- Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & EfficacyCompletedNCT00615290Results posted
- VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ PatientsCompletedNCT00561925Phase 3Results posted
- Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)CompletedNCT00552240Phase 4Results posted
- Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected PatientsCompletedNCT00543803Results posted
- Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.CompletedNCT00531206Results posted
- Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive PatientsCompletedNCT00530920Phase 2Results posted
- Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PITerminatedNCT00517192Phase 3Results posted
- Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot EvaluationTerminatedNCT00447902Phase 3Results posted
- SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoCTerminatedNCT00440271Phase 3Results posted
- Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive AdultsCompletedNCT00389207Phase 3Results posted
- Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected SubjectsCompletedNCT00146328Phase 2/3Results posted
- Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)CompletedNCT00144170Phase 3Results posted
- Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected ChildrenCompletedNCT00076999Phase 1Results posted
- Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)CompletedNCT00054717Phase 3Results posted
- Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected SubjectsCompletedNCT02251223Phase 1/2
- Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without TipranavirCompletedNCT02249130Phase 2
- Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 PatientsTerminatedNCT02239835Phase 2
- Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV PatientsCompletedNCT02238314Phase 2
- Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic FailureCompletedNCT02232581Phase 2
- Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIVTerminatedNCT02229760Phase 1/2
- Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected SubjectsCompletedNCT02194179Phase 1
- Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy RegimenCompletedNCT02191332
- Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) RegimensCompletedNCT02191319
- Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®CompletedNCT02191293
- Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological SuppressionCompletedNCT02191202
- Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected PatientsCompletedNCT02184299Phase 4
- Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected PatientsTerminatedNCT02184286Phase 1
- Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ PatientsCompletedNCT02184078Phase 4
- Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected WomenCompletedNCT02182791Phase 1
- Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive AdultsTerminatedNCT02182765Phase 1
- Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive PatientsCompletedNCT02181946Phase 4
- Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive WomenCompletedNCT02181933Phase 3
- Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.WithdrawnNCT01276990Phase 1
- An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.Approved for marketingNCT00933205
- Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV CohortWithdrawnNCT00805857
- Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)CompletedNCT00615563
- Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced PopulationCompletedNCT00614302
- Case-Control Viramune (Nevirapine) Toxicogenomics StudyCompletedNCT00310843
- Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated PatientsTerminatedNCT00294372Phase 2
- 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining StudyCompletedNCT00275444Phase 2
- Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ PatientsCompletedNCT00274001Phase 4
- Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric PatientsCompletedNCT00273975Phase 2
- Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment OptionsCompletedNCT00144287Phase 3
- An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ SubjectsCompletedNCT00144261Phase 4
- A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic FunctionsCompletedNCT00144248Phase 4
- A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.TerminatedNCT00144105Phase 2
- Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 InfectionApproved for marketingNCT00097799
- Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV InfectionApproved for marketingNCT00062660
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected PatientsCompletedNCT00056641Phase 2
- Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected IndividualsCompletedNCT00034866Phase 2
- The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken StavudineCompletedNCT00002381Phase 1
- The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV DrugsCompletedNCT00002368Phase 3
- The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the DiseaseCompletedNCT00002324Phase 2
- A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ CellCompletedNCT00002323Not applicable
- An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.CompletedNCT00002194Phase 1
- An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV DiseaseCompletedNCT00002166Phase 3
- An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)CompletedNCT00000649Phase 1